Find in Library

401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

oleh: Marcin Kowanetz, Manish Sharma, Jeeyun Lee, Leisha Emens, Keun-Wook Lee, Yoon-Koo Kang, Paula Pohlmann, Glenn Hanna, Ecaterina Ileana Dumbrava, Daniel Catenacci, Dejan Juric, Bob Li, Kathleen Moore, Mark Pegram, Antoinette Tan, Shelley Ackerman, Heidi LeBlanc, David Dornan, Michael Alonso, Edith Perez